Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,460,430
  • Shares Outstanding, K 576,857
  • Annual Sales, $ 2,378 M
  • Annual Income, $ 770,950 K
  • EBIT $ 1,560 M
  • EBITDA $ 1,592 M
  • 60-Month Beta 0.40
  • Price/Sales 11.33
  • Price/Cash Flow 9.62
  • Price/Book 2.73

Options Overview Details

View History
  • Implied Volatility 49.99% (-8.46%)
  • Historical Volatility 19.84%
  • IV Percentile 78%
  • IV Rank 54.58%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 7) 2.01 (4.39%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 48
  • Volume Avg (30-Day) 589
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 14,516
  • Open Int (30-Day) 13,549
  • Expected Range 43.86 to 47.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.17
  • Number of Estimates 2
  • High Estimate 1.18
  • Low Estimate 1.17
  • Prior Year 1.06
  • Growth Rate Est. (year over year) +10.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.67 +2.67%
on 02/20/26
47.86 -4.16%
on 03/04/26
+1.07 (+2.39%)
since 02/12/26
3-Month
37.83 +21.25%
on 12/16/25
47.86 -4.16%
on 03/04/26
+7.48 (+19.48%)
since 12/12/25
52-Week
29.66 +54.65%
on 04/07/25
47.86 -4.16%
on 03/04/26
+13.02 (+39.63%)
since 03/12/25

Most Recent Stories

More News
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be...

RPRX : 45.87 (-1.76%)
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 45.87 (-1.76%)
ZYME : 23.23 (-7.60%)
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 45.87 (-1.76%)
ZYME : 23.23 (-7.60%)
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46 th Annual Health Care Conference on March...

RPRX : 45.87 (-1.76%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

RPRX : 45.87 (-1.76%)
MTD : 1,168.00 (-4.96%)
RVTY : 84.76 (-5.43%)
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call

5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call

RPRX : 45.87 (-1.76%)
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

RPRX : 45.87 (-1.76%)
Royalty Pharma Reports Q4 and Full Year 2025 Results

Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of...

RPRX : 45.87 (-1.76%)
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

RPRX : 45.87 (-1.76%)
3 Mid-Cap Stocks We Keep Off Our Radar

3 Mid-Cap Stocks We Keep Off Our Radar

RPRX : 45.87 (-1.76%)
IFF : 70.01 (+1.88%)
NLY : 22.01 (-2.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 47.22
2nd Resistance Point 46.86
1st Resistance Point 46.36
Last Price 45.87
1st Support Level 45.50
2nd Support Level 45.14
3rd Support Level 44.64

See More

52-Week High 47.86
Last Price 45.87
Fibonacci 61.8% 40.91
Fibonacci 50% 38.76
Fibonacci 38.2% 36.61
52-Week Low 29.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar